Results 151 to 160 of about 205,861 (285)

Recurrent Neutropenia [PDF]

Archives of Disease in Childhood, 1951
openaire   +2 more sources

Advances in mucosal injury mechanisms in radiation‐induced esophagitis associated with thoracic radiotherapy

Precision Radiation Oncology, EarlyView.
There is no specific therapeutic drug regimen for radiation esophagitis. In previous studies, radiation esophagitis was considered a self‐limiting disease; however, current clinical approaches are limited to symptomatic treatment, which yields unsatisfactory therapeutic outcomes.
Hao Zhang, Liangxue Luo, Chaofen Zhao, Bibo Wu, Jing Zhang, Lingfeng Liu, Bing Lu, Shengfa Su   +7 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system. [PDF]

Ther Adv Psychopharmacol
Kang N, Jang JS, Joo SW, Lee JH, Jeong JH, Kim M, Ahn YM, Kwon JS, Kim YS, Lee JS, Kim SH.   +10 more
europepmc   +1 more source

Drug Neutropenia [PDF]

BMJ, 1970
openaire   +2 more sources

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Severe Immune Neutropenia Responsive to Ruxolitinib. [PDF]

EJHaem
Schwarzkopf R, Chen AAY, Elsharawi I, O'Reilly T, Chen LYC.   +4 more
europepmc   +1 more source

Chronic Neutropenia

Medicine, 1979
D C, Dale, D, Guerry, J R, Wewerka, J M, Bull, M J, Chusid   +4 more
openaire   +2 more sources

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

Respirology, EarlyView.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis. [PDF]

Breast Cancer Res Treat
Tam G, Waddell D, Freeman JQ, Chen N, Yang H.   +4 more
europepmc   +1 more source